XBIO Hands 85% of Itself to a Swiss Blood-Cleaning Startup — Is the Remaining Sliver Worth the Gamble?

Shares of Xenetic Biosciences (XBIO) cratered 22% to $3.32 on September 16 after the micro-cap biotech disclosed a reverse merger with Santersus AG, a private Swiss medical-device company, that will leave existing XBIO stockholders holding just 15% of the combined entity. The deal raises an uncomfortable question: Does a company with a ~$7.6 million market cap and only two employees have any leverage in a transaction this lopsided?

• The Deal Is Really a Takeover Wrapped in a Stock Swap. Under a Share Exchange Agreement signed September 14, Xenetic will acquire the entire issued share capital of Santersus, making the Swiss firm a wholly owned subsidiary. But the 85/15 ownership split means Santersus shareholders, not Xenetic's, will control the resulting company. Xenetic currently has roughly 2.3 million shares outstanding and a market cap near $10 million at recent prices — implying the market is valuing the Santersus assets coming in at roughly $45–55 million. The transaction still requires shareholder approval and is expected to close in Q4 2026.

• A Board Member Founded the Company Being Acquired. Xenetic board member Dmitry Genkin is the founder and board member of Santersus AG.

He has also served as Executive Chairman of PJSC Pharmsynthez, a stockholder of Xenetic, since 2005. That web of connections means investors should scrutinize whether the deal was negotiated at arm's length. The company had already disclosed that it was exploring a sale or reverse merger, warning such a move "may dilute current stockholders."

• Santersus Brings Real FDA Credentials, but No Revenue Yet. Santersus holds two FDA Breakthrough Device Designations — for a blood-purification device that filters harmful inflammatory molecules — one for sepsis and one for severe lupus.

It recently completed a Series A financing led by Norcliffe Capital and joined by Terumo Ventures. Those are meaningful validations, but the device is still pre-commercial, with pivotal trials still being prepared and the Series A funding the path toward regulatory approval.

• XBIO Was Already a Shell Looking for a Lifeline. Xenetic had just two employees and trailing twelve-month revenue of only $2.98 million.

A stock originally listed at $612 per share has lost over 99% of its value over the past decade. The reverse merger follows a broader biotech trend: 2026 has seen 17 reverse-merger deals, the most since 2018. For XBIO shareholders, the bet is now almost entirely on whether Santersus's blood-filtering device can clear clinical trials and reach the market — with their stake shrunken to a fraction of what it was.